Unlocking The Potential Of Gamma Delta T Cell-Based Therapies

By Dr. Cheng Kang Zhang, Associate Director, R&D, Lonza Bioscience Solutions

Lonza is advancing immunotherapy by pioneering two novel gamma delta T cell expansion methods, designed to bypass HLA antigen presentation and minimize graft-versus-host disease risk, thereby enhancing patient safety.

Dr. Cheng Kang Zhang, Associate Director, R&D, Lonza Bioscience Solutions, highlights two distinct clinical-scale expansion techniques.

Zoledronic Acid Activation:

• This method excels in expanding Vγ9Vδ2 T cells, yielding over 31 billion cells within two weeks.
• These cells exhibit potent anti-tumor activity.

Anti-CD3/CD28 Activation:

• This approach effectively expands both Vγδ1 and Vγ9Vδ2 T cells, ensuring high purity and functional integrity.
• It achieves an 80% transduction efficiency, making it highly suitable for large-scale clinical applications.

These methods provide exceptional versatility and scalability, facilitating the production of therapeutic doses for personalized treatments. Lonza's innovative solutions empower researchers and clinicians to expand T cells efficiently and reproducibly, pushing the boundaries of advanced immunotherapy.